Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is a humanized monoclonal anti-body targeting the epidermal growth factor
receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different
indications. Nimotuzumab has demonstrated a unique clinical profile, where anti-tumor
activity was observed in absence of severe skin, renal, gastrointestinal mucosa toxicities
commonly associated with EGFR-targeting antibodies. Nimotuzumab has been granted approval for
use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in
many countries. The investigators compared docetaxel plus nimotuzumab with docetaxel alone in
chemotherapy-refractory/resistant patients with advanced EGFR-positive non-small-cell lung
cancer to assess the efficacy and safety.